KRAS and neoplasm: Tumors with LSM12, LSM14A, and LSM14B overexpression also exhibited notably higher expression of critical molecules overlapped between the mTOR signaling pathway and T-cell receptor signaling pathway, namely, AKT2, CHUK, GRB2, GSK3B, IKBKB, KRAS, MAP2K1, MAPK1, NRAS, PDPK1, PIK3CA, PIK3CB, RAF1, RHOA, SOS1, and SOS2, which may be the potential targets of LSM12, LSM14A, and LSM14B for tumor immunity in HCC.